中英文縮略詞表

中英文縮略詞表

AASLD(American Association for the Study of Liver Disease) 美國肝病學(xué)會

ACEI(angiotensin converting enzyme inhibitors) 血管緊張素轉(zhuǎn)換酶抑制劑

AKI(acute kidney injury) 急性腎損傷

ARB(angiotensin receptor blocker) 血管緊張素受體拮抗劑

ascites 腹水

BA(bacterascite) 細菌性腹水

CART(cell-free and concentrated ascites reinfusion therapy) 無細胞腹水濃縮回輸

Child-Pugh 肝功能分級

CNNA(culture negative neutrocyticascites) 腹水培養(yǎng)陰性的中性粒細胞增多性腹水CT(computed tomography) X線計算機斷層攝影

EASL(European Association for the Study of the Liver) 歐洲肝病學(xué)會

ESBL(extended-spectrum beta-lactamase) 超廣譜β內(nèi)酰胺酶

FDA(Food and Drug Administration) （美國）食品及藥物管理局

GFR(glomerular fi ltration rate) 腎小球濾過率

GRADE(grading of recommendations assessment development and evaluation) 推薦分級的評估，制定與評價

HRS(hepatorenal syndrome) 肝腎綜合征

ICA(International-Club of Ascites) 國際腹水俱樂部

LDH(lactic acid dehydrogenase) 乳酸脫氫酶

MDR(multi-drug resistance) 多重耐藥

MNB(monomicrobial nonneutrocytic bacterascites) 中性粒細胞不增高單株細菌性腹水

MRI(magnetic resonance imaging) 磁共振成像

NSAIDs(nonsteroidal anti-in fl ammatory drugs) 非甾體類消炎藥物

nosocomial SBP 院內(nèi)感染自發(fā)性細菌性腹膜炎

PCT(procalcitonin) 降鈣素原

peritoneal malignancy 腹腔惡性腫瘤

PICD(post-paracentesis circulatory dysfunction) 大量放腹水后循環(huán)障礙

PMN(polymorph nuclear) 中性粒細胞

RAAS(renin-angiotensin-aldosterone system) 腎素-血管緊張素-醛固酮系統(tǒng)

RRT(renal replacement therapy) 連續(xù)性血液濾過

SAAG(serum-ascites albumin gradient) 血清-腹水白蛋白梯度

SBP(spontaneous bacterial peritonitis) 自發(fā)性細菌性腹膜炎

SCr(serum creatinine) 血肌酐

TGF β(transforming growth factor beta) 轉(zhuǎn)化生長因子β

TIPS(transjugular intrahepatic potorsystemic shunt) 經(jīng)頸靜脈肝內(nèi)門體分流術(shù)

VRE(vancomycin resistant enterococci) 萬古霉素耐藥腸球菌

WGO(World Gastroenterology Organization) 世界胃腸病學(xué)組織

XDR(extensively drug-resistant) 泛耐藥

[1]Planas R, Montoliu S, Balleste B, Rivera M, Miquel M, Masnou H,Galeras JA, Gimenez MD, Santos J, Cirera I, Morillas RM, Coll S,Sola R. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006 Nov;4(11):1385-1394.

[2]Krag A, Bendtsen F, Henriksen JH, Moller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010 Jan;59(1):105-110.

[3]EASL clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010 Sep;53(3):397-417.

[4]Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013 Apr;57(4):1651-1653.

[5]Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009 Jun;49(6):2087-2107.

[6]Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006 Oct;55 Suppl 6:vi1-12.

[7]Huang LL, Xia HH, Zhu SL. Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites. J Clin Transl Hepatol. 2014 Mar;2(1):58-64.

[8]Wardeh R, Lee JG, Gu M. Endoscopic ultrasound-guided paracentesis of ascitic fluid: a morphologic study with ultrasonographic correlation. Cancer Cytopathol. 2011 Feb 25;119(1):27-36.

[9]Rodriguez Vargas BO, Monge Salgado E, Montes Teves P, Salazar Ventura S, Guzman Calderon E. Diagnostic of ascites due to portal hypertension: accuracy of the serum-ascites albumin gradient and protein analises in ascitic fluid. Rev Gastroenterol Peru. 2014 Jan-Mar;34(1):23-28.

[10]Demirel U, Karincaoglu M, Harputluoglu M, Ates M, Seckin Y,Yildirim B, Hilmioglu F. Two findings of portal hypertension:evaluation of correlation between serum-ascites albumin gradient and esophageal varices in non-alcoholic cirrhosis. Turk J Gastroenterol. 2003 Dec;14(4):219-222.

[11]Dittrich S, Yordi LM, de Mattos AA. The value of serum-ascites albumin gradient for the determination of portal hypertension in the diagnosis of ascites. Hepatogastroenterology. 2001 Jan-Feb;48(37):166-168.

[12]Hou W, Sanyal AJ. Ascites: diagnosis and management. Med Clin North Am. 2009 Jul;93(4):801-817, vii.

[13]Patel YA, Muir AJ. Evaluation of New-Onset Ascites. Jama. 2016 Jul 19;316(3):340-341.

[14]Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL, Li B, Dong PL, Li L, Ding HG. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. World J Gastroenterol.2014 Aug 28;20(32):11400-11405.

[15]Spahr L, Villeneuve JP, Tran HK, Pomier-Layrargues G.Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites. Hepatology. 2001 Jan;33(1):28-31.

[16]Akiyama S, Ikeda K, Sezaki H, Fukushima T, Sorin Y, Kawamura Y, Saitoh S, Hosaka T, Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Kumada H. Therapeutic effects of short- and intermediate-term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis. Hepatol Res. 2015 Nov;45(11):1062-1070.

[17]Jia JD, Xie W, Ding HG, Mao H, Guo H, Li Y, Wang X, Wang JF,Lu W, Li CZ, Mao Y, Wang GQ, Gao YQ, Wang B, Zhang Q, Ge Y,Wong VW. Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study. Ann Hepatol. 2017 Jan-Feb;16(1):123-132.

[18]Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, Krasa H, Ouyang J, Torres VE, Czerwiec FS, Zimmer CA.Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database. Drug Saf. 2015 Nov;38(11):1103-1113.

[19]Salerno F, Guevara M, Bernardi M, Moreau R, Wong F, Angeli P,Garcia-Tsao G, Lee SS. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis.Liver Int. 2010 Aug;30(7):937-947.

[20]Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, Ganger D, Jamil K, Pappas SC. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.Gastroenterology. 2016 Jun;150(7):1579-1589.e1572.

[21]Wong F, Pappas SC, Boyer TD, Sanyal AJ, Bajaj JS, Escalante S, Jamil K. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome. Clin Gastroenterol Hepatol. 2017 Feb;15(2):266-272.e261.

[22]Ali A, Farid S, Amin M, Kassem M, Al-Garem N. Clinical study on the therapeutic role of midodrine in non azotemic cirrhotic patients with tense ascites: a double-blind, placebo-controlled, randomized trial. Hepatogastroenterology. 2014 Oct;61(135):1915-1924.

[23]Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A,Moreau R, Jalan R, Sarin SK, Piano S, Moore K, Lee SS, Durand F, Salerno F, Caraceni P, Kim WR, Arroyo V, Garcia-Tsao G.Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015 Apr;62(4):968-974.

[24]Bernardi M. Optimum use of diuretics in managing ascites in patients with cirrhosis. Gut. 2010 Jan;59(1):10-11.

[25]Angeli P, Fasolato S, Mazza E, Okolicsanyi L, Maresio G, Velo E,Galioto A, Salinas F, D'Aquino M, Sticca A, Gatta A. Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial.Gut. 2010 Jan;59(1):98-104.

[26]Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, Shibuya A,Seike M, Nagoshi S, Segawa M, Tsubouchi H, Moriwaki H, Kato A,Hashimoto E, Michitaka K, Murawaki T, Sugano K, Watanabe M,Shimosegawa T. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol. 2016 Jul;51(7):629-650.

[27]Uojima H, Kinbara T, Hidaka H, Sung JH, Ichida M, Tokoro S,Masuda S, Takizawa S, Sasaki A, Koizumi K, Egashira H, Kako M.Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites. Hepatol Res. 2016 Apr 05.

[28]Lenz K, Buder R, Kapun L, Voglmayr M. Treatment and management of ascites and hepatorenal syndrome: an update.Therap Adv Gastroenterol. 2015 Mar;8(2):83-100.

[29]Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T,Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C,Karlberg BE, Wester PO, Bjorck JE. Effect of angiotensinconverting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet.1999 Feb 20;353(9153):611-616.

[30]Guevara M, Fernandez-Esparrach G, Alessandria C, Torre A, Terra C, Montana X, Piera C, Alvarez ML, Jimenez W, Gines P, Arroyo V. Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology. 2004 Sep;40(3):646-651.

[31]Sakaida I, Kawazoe S, Kajimura K, Saito T, Okuse C, Takaguchi K,Okada M, Okita K. Tolvaptan for improvement of hepatic edema:A phase 3, multicenter, randomized, double-blind, placebocontrolled trial. Hepatol Res. 2014 Jan;44(1):73-82.

[32]Le S, Spelman T, Chong CP, Ha P, Sahhar L, Lim J, He T,Heerasing N, Sievert W. Could Adherence to Quality of Care Indicators for Hospitalized Patients With Cirrhosis-Related Ascites Improve Clinical Outcomes? Am J Gastroenterol. 2016 Jan;111(1):87-92.

[33]Yakar T, Demir M, Dogan O, Parlakgumus A, Ozer B, Serin E.High Dose Oral Furosemide with Salt Ingestion in the Treatment of Refractory Ascites of Liver Cirrhosis. Clin Invest Med. 2016 Dec 01;39(6):27502.

[34]Tandon P, Raman M, Mourtzakis M, Merli M. A practical approach to nutritional screening and assessment in cirrhosis. Hepatology.2016 Dec 27.

[35]范春蕾, 吳燕京, 丁惠國, 張斌, 董培玲, 周莉, 平春霞, 趙春惠. 慢性重型病毒性肝炎的能量代謝及糖、蛋白質(zhì)、脂肪氧化.中國臨床營養(yǎng)雜志. 2006;14(2):110-114.

[36]曹海霞, 范建高. 肝硬化患者營養(yǎng)評估及營養(yǎng)支持治療. 實用肝臟病雜志. 2014(5):459-462.

[37]Vincent JL, De Backer D, Wiedermann CJ. Fluid management in sepsis: The potential beneficial effects of albumin. J Crit Care. 2016 Oct;35:161-167.

[38]Artigas A, Wernerman J, Arroyo V, Vincent JL, Levy M. Role of albumin in diseases associated with severe systemic inflammation:Pathophysiologic and clinical evidence in sepsis and in decompensated cirrhosis. J Crit Care. 2016 Jun;33:62-70.

[39]Alessandria C, Elia C, Mezzabotta L, Risso A, Andrealli A,Spandre M, Morgando A, Marzano A, Rizzetto M. Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study. Dig Liver Dis. 2011 Nov;43(11):881-886.

[40]Abd Elaal MM, Zaghloul SG, Bakr HG, Ashour MA, Abdel-Aziz-El-Hady H, Khalifa NA, Amr GE. Evaluation of different therapeutic approaches for spontaneous bacterial peritonitis. Arab J Gastroenterol. 2012 Jun;13(2):65-70.

[41]Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a metaanalysis of randomized trials. Hepatology. 2012 Apr;55(4):1172-1181.

[42]Gaetano JN, Micic D, Aronsohn A, Reddy G, Te H, Reau NS,Jensen D. The benefit of paracentesis on hospitalized adults with cirrhosis and ascites. J Gastroenterol Hepatol. 2016 May;31(5):1025-1030.

[43]Gaba RC, Parvinian A, Casadaban LC, Couture PM, Zivin SP,Lakhoo J, Minocha J, Ray CE, Jr., Knuttinen MG, Bui JT. Survival benefit of TIPS versus serial paracentesis in patients with refractory ascites: a single institution case-control propensity score analysis.Clin Radiol. 2015 May;70(5):e51-57.

[44]Bohn KA, Ray CE, Jr. Repeat Large-Volume Paracentesis Versus Tunneled Peritoneal Catheter Placement for Malignant Ascites: A Cost-Minimization Study. AJR Am J Roentgenol. 2015 Nov;205(5):1126-1134.

[45]Lungren MP, Kim CY, Stewart JK, Smith TP, Miller MJ. Tunneled peritoneal drainage catheter placement for refractory ascites:single-center experience in 188 patients. J Vasc Interv Radiol.2013 Sep;24(9):1303-1308.

[46]Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A,Mathurin P, Otal P, Cabarrou P, Peron JM, Vinel JP. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites. Gastroenterology. 2017 Jan;152(1):157-163.

[47]Porcel JM. Management of refractory hepatic hydrothorax. Curr Opin Pulm Med. 2014 Jul;20(4):352-357.

[48]Kozaki K, M II, Takagi T, Fukuda T, Sanpei T, Terunuma Y, Yatabe Y, Akano K. Cell-Free and Concentrated Ascites Reinfusion Therapy for Decompensated Liver Cirrhosis. Ther Apher Dial. 2016 Aug;20(4):376-382.

[49]Tapping CR, Ling L, Razack A. PleurX drain use in the management of malignant ascites: safety, complications, longterm patency and factors predictive of success. Br J Radiol. 2012 May;85(1013):623-628.

[50]中華醫(yī)學(xué)會肝病學(xué)分會, 中華醫(yī)學(xué)會感染病學(xué)分會. 慢性乙型肝炎防治指南(2015更新版). 中華肝臟病雜志.2015;23(12):888-905.

[51]中華醫(yī)學(xué)會肝病學(xué)分會, 中華醫(yī)學(xué)會感染病學(xué)分會. 丙型肝炎防治指南(2015更新版). 中華肝臟病雜志. 2015;23(12):906-923.

[52]盧瑋，高玉華，王珍子，蔡玉石，楊宇晴，苗玉麒，裴斐，劉學(xué)思，莊輝. 安絡(luò)化纖丸對肝纖維化大鼠轉(zhuǎn)化生長因子β1及相應(yīng)信號通路的影響. 中華肝臟病雜志. 2017;25(4):257-262.

[53]肖定洪, 顧杰, 蔡虹, 等. 扶正化瘀膠囊預(yù)防肝硬化患者食管靜脈曲張破裂出血的隨機對照多中心臨床研究. 中華肝臟病雜志. 2014, 22(08): 594-599.

[54]董佳佳，陳永平，王曉東，許爛漫，蕭云蕾，吳和，黃思思，杜珊潔，陳瑞聰. 復(fù)方鱉甲軟肝片聯(lián)合恩替卡韋治療慢性乙型肝炎伴脾功能亢進患者的臨床療效. 中華肝臟病雜志.2016;34(8):501-503.

[55]董培玲, 丁惠國. 肝硬化繼發(fā)感染:挑戰(zhàn)與對策. 北京醫(yī)學(xué).2011;33(9):763-766.

[56]Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol. 2012;56 Suppl 1:S1-12.

[57]Zhu LC, Xu L, He WH, Wu W, Zhu X. A quick screening model for symptomatic bacterascites in cirrhosis. Saudi J Gastroenterol. 2016 Jul-Aug;22(4):282-287.

[58]Na SH, Kim EJ, Nam EY, Song KH, Choe PG, Park WB, Bang JH, Kim ES, Park SW, Kim HB, Oh MD, Kim NJ. Comparison of clinical characteristics and outcomes of spontaneous bacterial peritonitis and culture negative neutrocytic ascites. Scand J Gastroenterol. 2017 Feb;52(2):199-203.

[59]Friedrich K, Nussle S, Rehlen T, Stremmel W, Mischnik A,Eisenbach C. Microbiology and resistance in first episodes of spontaneous bacterial peritonitis: implications for management and prognosis. J Gastroenterol Hepatol. 2016 Jun;31(6):1191-1195.

[60]Pericleous M, Sarnowski A, Moore A, Fijten R, Zaman M. The clinical management of abdominal ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: a review of current guidelines and recommendations. Eur J Gastroenterol Hepatol. 2016 Mar;28(3):e10-18.

[61]Joseph SS, John EM and John SB, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children:guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010:50(15);133-164.

[62]John EM, Jeffrey MT and Addison KM, et al. The Surgical Infection Society revised guidelines on management of intra-abdominal infection.Surgical Infections. 2017:18(1);1-76.

[63]Oliveira AM, Branco JC, Barosa R, Rodrigues JA, Ramos L,Martins A, Karvellas CJ, Cardoso FS. Clinical and microbiological characteristics associated with mortality in spontaneous bacterial peritonitis: a multicenter cohort study. Eur J Gastroenterol Hepatol.2016 Oct;28(10):1216-1222.

[64]Piano S, Fasolato S, Salinas F, Romano A, Tonon M, Morando F, Cavallin M, Gola E, Sticca A, Loregian A, Palu G, Zanus G,Senzolo M, Burra P, Cillo U, Angeli P. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial. Hepatology. 2016 Apr;63(4):1299-1309.

[65]Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, Vargas V, Soriano G, Guevara M, Gines P, Rodes J.Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999 Aug 05;341(6):403-409.

[66]Thevenot T, Bureau C, Oberti F, Anty R, Louvet A, Plessier A,Rudler M, Heurgue-Berlot A, Rosa I, Talbodec N, Dao T, Ozenne V, Carbonell N, Causse X, Goria O, Minello A, De Ledinghen V,Amathieu R, Barraud H, Nguyen-Khac E, Becker C, Paupard T,Botta-Fridlung D, Abdelli N, Guillemot F, Monnet E, Di Martino V. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J Hepatol.2015 Apr;62(4):822-830.

[67]Zhang Z, Chen K. Vasoactive agents for the treatment of sepsis.Ann Transl Med. 2016 Sep;4(17):333.

[68]Fiore M. Letter: the emergence of multi-drug resistant spontaneous bacterial peritonitis: a new challenge for the hepatologist? Aliment Pharmacol Ther. 2016 Apr;43(8):944-945.

[69]Lahmer T, Brandl A, Rasch S, Schmid RM, Huber W. Fungal Peritonitis: Underestimated Disease in Critically Ill Patients with Liver Cirrhosis and Spontaneous Peritonitis. PLoS One.2016;11(7):e0158389.

[70]國家衛(wèi)生計生委合理用藥專家委員會, 全國細菌耐藥監(jiān)測網(wǎng).2015年全國細菌耐藥監(jiān)測報告. 中國執(zhí)業(yè)藥師. 2016:3; 3-8.

[71]Ponziani FR, Gerardi V, Pecere S, D'Aversa F, Lopetuso L, Zocco MA, Pompili M, Gasbarrini A. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol. 2015 Nov 21;21(43):12322-12333.

[72]Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L,Navasa M, Claria J, Rimola A, Arroyo V, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993 Jul;105(1):229-236.

[73]Lavayssiere L, Kallab S, Cardeau-Desangles I, Nogier MB,Cointault O, Barange K, Muscari F, Rostaing L, Kamar N. Impact of molecular adsorbent recirculating system on renal recovery in type-1 hepatorenal syndrome patients with chronic liver failure. J Gastroenterol Hepatol. 2013 Jun;28(6):1019-1024.

[74]Wong F, Blendis L. New challenge of hepatorenal syndrome:prevention and treatment. Hepatology. 2001 Dec;34(6):1242-1251.

[75]Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology. 2010 Feb;51(2):576-584.

[76]丁曉紅, 顧建英. 特利加壓素治療Ⅱ型肝腎綜合征的臨床療效觀察. 臨床肝膽病雜志. 2015(5):745-748.

[77]徐小元, 鄭穎穎. 肝腎綜合征——縮血管還是擴血管? 臨床肝膽病雜志. 2011;27(8):801-803,817.

[78]Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, Bernardi M, Romanelli RG, Colletta C, Salinas F, Di Giacomo A, Ridola L, Fornasiere E, Caraceni P, Morando F, Piano S, Gatta A, Angeli P. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome:A randomized trial. Hepatology. 2015 Aug;62(2):567-574.

[79]Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, Sharma AK, Choudhary NS, Chawla Y, Nain CK. Noradrenaline vs.terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012 Jun;56(6):1293-1298.

[80]張園園, 馬娟娟, 白嵐. 去甲腎上腺素與特利加壓素治療肝腎綜合征的療效比較. 實用醫(yī)學(xué)雜志. 2015(5):807-810.

[81]Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG,Czerwiec FS, Orlandi C. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006 Nov 16;355(20):2099-2112.

[82]Smith M, Durham J. Evolving Indications for Tips. Tech Vasc Interv Radiol. 2016 Mar;19(1):36-41.

[83]Bai M, Qi XS, Yang ZP, Yang M, Fan DM, Han GH. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol.2014 Mar 14;20(10):2704-2714.

[84]Sourianarayanane A, Raina R, Garg G, McCullough AJ, O'Shea RS. Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients. Int Urol Nephrol. 2014 Apr;46(4):793-800.

[85]Wong F, Raina N, Richardson R. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. Gut. 2010 Mar;59(3):381-386.

[86]Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gulberg V, Sigal S, Bexon AS, Teuber P.Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl. 2011 Nov;17(11):1328-1332.

[87]Bossen L, Krag A, Vilstrup H, Watson H, Jepsen P.. Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients.. Hepatology. 2016 Jun;63(6):1968-76.

編后語編輯部對所刊載內(nèi)容未作編輯加工